The potential of survivin as a non-invasive diagnostic marker for endometriosis in patients with type 1 diabetes mellitus
This study investigated endometriosis prevalence in type 1 diabetes patients and assessed serum survivin levels as a potential non-invasive diagnostic marker.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This study retrospectively analyzed 2,316 medical records from 2010–2021 to estimate the prevalence and clinical characteristics of endometriosis among women with type 1 diabetes mellitus, then conducted a prospective case-control study (137 patients) measuring serum survivin on menstrual cycle days 5–7 across four groups (type 1 diabetes with endometriosis, endometriosis alone, type 1 diabetes alone, and healthy controls). Using binary logistic regression, the authors identified a 1.11% prevalence of endometriosis in the type 1 diabetes cohort and derived risk indicators and probability cutoffs (>50%) based on survivin levels and clinical factors to support a diagnostic prognostic model. The paper’s limitation is that, despite addressing noninvasive biomarkers, it does not fully specify the diagnostic reference standard within the provided text beyond using recorded case histories. This paper is centrally about endometriosis — developing a survivin-based non-invasive diagnostic prognostic model specifically in women with type 1 diabetes mellitus.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Abstract
Full text
8,940 characters
· extracted from
oa-doi-fallback
· 5 sections
· click to expand
Abstract
Materials and methods
Results
Conclusions
Keywords
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (20)
- A systematic review on the prevalence of endometriosis in women via openalex
- Biomarkers for the Noninvasive Diagnosis of Endometriosis: State of the Art and Future Perspectives via openalex
- BIRC5/Survivin Expression as a Non-Invasive Biomarker of Endometriosis via openalex
- Blood biomarkers for the non-invasive diagnosis of endometriosis via openalex
- Co-morbidity of type 1 diabetes and endometriosis: bringing a new paradigm into focus via openalex
- Endometriosis via openalex
- Survivin Gene Expression in Endometriosis via openalex
- TGFBI as a candidate biomarker for non-invasive diagnosis of early-stage endometriosis via openalex
- The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis via openalex
- TNFα-induced IKKβ complex activation influences epithelial, but not stromal cell survival in endometriosis via openalex
- Treg and NK cells related cytokines are associated with deep rectosigmoid endometriosis and clinical symptoms related to the disease via openalex
- W3011999184 via openalex
- W3016301537 via openalex
- W3204298406 via openalex
- W2410834892 via openalex
- W2010204260 via openalex
- W2805387664 via openalex
- W1579150364 via openalex
- W2516721496 via openalex
- W3010796637 via openalex
Cited by (2)
Source provenance
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00